Malignant Tumor Treatment Technologies, Inc.

Based in Sakai-shi, Japan, Malignant Tumor Treatment Technologies, Inc. focuses on developing innovative treatments for malignant tumors, aiming to enhance patient outcomes through advanced therapies. Malignant Tumor Treatment Technologies, Inc. was founded in 2018 in Sakai-shi, Japan.

The company specializes in cancer treatment technologies and has completed 2 significant deals to date, with the most recent funding round occurring on June 22, 2022. The firm has not undergone notable strategic pivots or structural changes since its inception. 株式会社MT3 (MT3, Inc. ) specializes in the development and commercialization of innovative treatments for malignant tumors, with a primary focus on their flagship product, Levritin® (レブリチン®).

This pharmaceutical is designed to target and inhibit specific pathways related to tumor growth and is aimed at improving patient outcomes in oncology. The company's suite of offerings includes not only Levritin® but also related cancer treatment technologies that leverage advanced research in molecular imaging and radiation therapy. The end users of these products primarily include oncologists, healthcare institutions, and patients diagnosed with various forms of cancer, particularly in markets such as Japan, the United States, and parts of Europe. The products are intended to address unmet medical needs in cancer therapy, promoting personalized treatment approaches that enhance therapeutic efficacy while minimizing side effects.

The revenue model for MT3, Inc. revolves around direct sales of its pharmaceutical products, particularly Levritin®, through arrangements with healthcare providers and pharmaceutical distributors. The company engages in partnerships with hospitals and clinics, facilitating access to their innovative cancer treatments for patients. Revenue is generated through product sales, structured around per prescription or bulk purchase agreements depending on the volume of treatments required by healthcare facilities.

Additionally, MT3 may explore collaborations with research institutions for clinical trials and studies, further solidifying its market presence and enhancing revenue streams. The pricing structure for Levritin® and other services is established based on competitive market analysis, aligning with industry standards for specialty pharmaceuticals. In June 2022, Malignant Tumor Treatment Technologies, Inc. raised an undisclosed amount in growth capital funding from new investors Wing Capital Partners and Gunma Regional Advanced Solution Partners.

The company plans to utilize this funding to support the design and launch of new products aimed at expanding its treatment portfolio. MT3 is targeting expansion into the United States and European markets by 2025, aiming to increase accessibility to its innovative treatments. The funding will also facilitate collaborations with research institutions to enhance clinical trials for Levritin® and related cancer therapies.